Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript
Cardiff Oncology, Inc. has provided an update on their Phase II CRDF-004 trial data regarding Onvansertib for treating first-line RAS-mutated metastatic colorectal cancer. The presentation took place during a conference call, featuring key participants from various research divisions. This update is part of ongoing efforts to advance treatment options for patients with this specific cancer type.
- ▪Cardiff Oncology, Inc. discussed updated Phase II CRDF-004 data on Onvansertib.
- ▪The data pertains to first-line RAS-mutated metastatic colorectal cancer.
- ▪The conference call included participants from multiple research divisions.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911452-cardiff-oncology-inc-crdf-discusses-updated-phase-ii-crdfminus-004-data-on-onvansertib-in"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
